Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide

References

• Berkhout B, Silverman RH, Jeang KT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989; 59:273-82; PMID:2478293; http://dx.doi.org/10.1016/0092-8674(89)90289-4
   PubMed Web of Science ®Google Scholar
• Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N, McCloskey T, Pahwa S, Verdin E. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275:1481-5; PMID:9045614; http://dx.doi.org/10.1126/science.275.5305.1481
   PubMed Web of Science ®Google Scholar
• Sforza F, Nicoli F, Gallerani E, Finessi V, Reali E, Cafaro A, Caputo A, Ensoli B, Gavioli R. HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. AIDS 2014; 28:1729-38; PMID:24841128; http://dx.doi.org/10.1097/QAD.0000000000000315
   PubMed Web of Science ®Google Scholar
• Li L, Li HS, Pauza CD, Bukrinsky M, Zhao RY. Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res 2005; 15:923-34; PMID:16354571; http://dx.doi.org/10.1038/sj.cr.7290370
   PubMed Web of Science ®Google Scholar
• van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78(Pt 8):1913-8; PMID:9266987
   PubMedGoogle Scholar
• Rodman TC, Pruslin FH, To SE, Winston R. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope. J Exp Med 1992; 175:1247-53; PMID:1373758; http://dx.doi.org/10.1084/jem.175.5.1247
   PubMed Web of Science ®Google Scholar
• Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005; 191:1321-4; PMID:15776379; http://dx.doi.org/10.1086/428909
   PubMed Web of Science ®Google Scholar
• Re MC, Vignoli M, Furlini G, Gibellini D, Colangeli V, Vitone F, La Placa M. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001; 21:81-9; PMID:11255101; http://dx.doi.org/10.1016/S1386-6532(00)00189-X
   PubMed Web of Science ®Google Scholar
• Richardson MW, Mirchandani J, Duong J, Grimaldo S, Kocieda V, Hendel H, Khalili K, Zagury JF, Rappaport J. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 2003; 57:4-14; PMID:12642031; http://dx.doi.org/10.1016/S0753-3322(02)00327-X
   PubMed Web of Science ®Google Scholar
• Zagury JF, Sill A, Blattner W, Lachgar A, Le Buanec H, Richardson M, Rappaport J, Hendel H, Bizzini B, Gringeri A, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998; 1:282-92; PMID:10195253
   PubMedGoogle Scholar
• Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, et al. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology 2014; 11:49; PMID:24961156; http://dx.doi.org/10.1186/1742-4690-11-49
   PubMed Web of Science ®Google Scholar
• Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643-50; PMID:10371502; http://dx.doi.org/10.1038/9488
   PubMed Web of Science ®Google Scholar
• Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Butto S, Fiorelli V, et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258-69; PMID:15308348; http://dx.doi.org/10.1016/j.vaccine.2004.03.009
   PubMed Web of Science ®Google Scholar
• Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, Annappa S, Salles JP, Loret EP. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology 2006; 3:8; PMID:16441880; http://dx.doi.org/10.1186/1742-4690-3-8
   PubMed Web of Science ®Google Scholar
• Bachler BC, Humbert M, Palikuqi B, Siddappa NB, Lakhashe SK, Rasmussen RA, Ruprecht RM. Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol 2013; 87:4403-16; PMID:23388727; http://dx.doi.org/10.1128/JVI.02888-12
   PubMed Web of Science ®Google Scholar
• Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, et al. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol 2009; 28:285-334; PMID:19811313; http://dx.doi.org/10.1080/08830180903013026
   PubMed Web of Science ®Google Scholar
• Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010; 5:e13540; PMID:21085635; http://dx.doi.org/10.1371/journal.pone.0013540
   PubMed Web of Science ®Google Scholar
• Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 2008; 22:2207-9; PMID:18832884; http://dx.doi.org/10.1097/QAD.0b013e32831392d4
   PubMed Web of Science ®Google Scholar
• Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009; 28:371-8; PMID:19879233; http://dx.doi.org/10.1016/j.vaccine.2009.10.038
   PubMed Web of Science ®Google Scholar
• Lehner T, Anton PA. Mucosal immunity and vaccination against HIV. AIDS 2002; 16(Suppl 4):S125-32; PMID:12699009
   PubMedGoogle Scholar
• Weaver EA, Nehete PN, Nehete BP, Yang G, Buchl SJ, Hanley PW, Palmer D, Montefiori DC, Ferrari G, Ng P, et al. Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One 2013; 8:e67574; PMID:23844034; http://dx.doi.org/10.1371/journal.pone.0067574
   PubMed Web of Science ®Google Scholar
• Eble PL, Weerdmeester K, van Hemert-Kluitenberg F, Dekker A. Intradermal vaccination of pigs against FMD with 1/10 dose results in comparable vaccine efficacy as intramuscular vaccination with a full dose. Vaccine 2009; 27:1272-8; PMID:19114077; http://dx.doi.org/10.1016/j.vaccine.2008.12.011
   PubMedGoogle Scholar
• Kunzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kursteiner O, Kompier R, Grimaldi R, Goudsmit J. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009; 27:3561-7; PMID:19464535; http://dx.doi.org/10.1016/j.vaccine.2009.03.062
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Sapru A, D'Costa PM, Pandit A, Madhusudana SN, Yajaman AB, Mangrule S, Gunale B, Bavdekar AR. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers. Vaccine 2013; 31:2719-22; PMID:23583817; http://dx.doi.org/10.1016/j.vaccine.2013.03.050
   PubMed Web of Science ®Google Scholar
• Frenck RW, Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB, Jr., Cate TR, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666-74; PMID:21699951; http://dx.doi.org/10.1016/j.vaccine.2011.06.010
   PubMed Web of Science ®Google Scholar
• Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29:8788-801; PMID:21968444; http://dx.doi.org/10.1016/j.vaccine.2011.09.077
   PubMed Web of Science ®Google Scholar
• Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 2006; 304:247-68; PMID:16989274
   PubMed Web of Science ®Google Scholar
• Barackman JD, Ott G, Pine S, O'Hagan DT. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin Diagn Lab Immunol 2001; 8:652-7; PMID:11329476
   PubMedGoogle Scholar
• Caputo A, Brocca-Cofano E, Castaldello A, De Michele R, Altavilla G, Marchisio M, Gavioli R, Rolen U, Chiarantini L, Cerasi A, et al. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine 2004; 22:2910-24; PMID:15246628; http://dx.doi.org/10.1016/j.vaccine.2003.12.025
   PubMed Web of Science ®Google Scholar
• Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, Ensoli B. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine 2008; 26:1214-27; PMID:18243435; http://dx.doi.org/10.1016/j.vaccine.2007.12.030
   PubMed Web of Science ®Google Scholar
• Nicoli F, Finessi V, Sicurella M, Rizzotto L, Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, et al. The HIV-1 Tat protein induces the activation of CD8(+) T cells and affects in vivo the magnitude and kinetics of antiviral responses. PLoS One 2013; 8:e77746; PMID:24223723; http://dx.doi.org/10.1371/journal.pone.0077746
   PubMed Web of Science ®Google Scholar
• Butto S, Fiorelli V, Tripiciano A, Ruiz-Alvarez MJ, Scoglio A, Ensoli F, Ciccozzi M, Collacchi B, Sabbatucci M, Cafaro A, et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 2003; 188:1171-80; PMID:14551888; http://dx.doi.org/10.1086/378412
   PubMed Web of Science ®Google Scholar
• Moreau E, Belliard G, Partidos CD, Pradezinsky F, Le Buanec H, Muller S, Desgranges C. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides. J Gen Virol 2004; 85:2893-901; PMID:15448351; http://dx.doi.org/10.1099/vir.0.80365-0
   PubMedGoogle Scholar
• Wu L. Biology of HIV mucosal transmission. Curr Opin HIV AIDS 2008; 3:534-40; PMID:18802490; http://dx.doi.org/10.1097/COH.0b013e32830634c6
   PubMedGoogle Scholar
• Zhou M, Zhang G, Ren G, Gnanadurai CW, Li Z, Chai Q, Yang Y, Leyson CM, Wu W, Cui M, et al. Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations. PLoS One 2013; 8:e63384; PMID:23700422; http://dx.doi.org/10.1371/journal.pone.0063384
   PubMed Web of Science ®Google Scholar
• de Aizpurua HJ, Russell-Jones GJ. Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding. J Exp Med 1988; 167:440-51; PMID:3346623; http://dx.doi.org/10.1084/jem.167.2.440
   PubMed Web of Science ®Google Scholar
• Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421-31; PMID:9342064; http://dx.doi.org/10.1097/00002030-199712000-00006
   PubMed Web of Science ®Google Scholar
• Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674-80; PMID:7935812; http://dx.doi.org/10.1038/371674a0
   PubMed Web of Science ®Google Scholar
• Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 2009; 182:2888-97; PMID:19234184; http://dx.doi.org/10.4049/jimmunol.0711406
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425
   PubMed Web of Science ®Google Scholar